These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22124105)

  • 1. FOLFIRINOX: a great leap forward, but for whom?
    dos Santos LV; de Andrade DP; Lima JP
    J Clin Oncol; 2012 Jan; 30(1):114-5; author reply 114. PubMed ID: 22124105
    [No Abstract]   [Full Text] [Related]  

  • 2. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFIRINOX: desert, oasis, or mirage?
    Ferrone CR
    Ann Surg Oncol; 2015 Apr; 22(4):1059-60. PubMed ID: 25490873
    [No Abstract]   [Full Text] [Related]  

  • 4. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
    Kim R
    Lancet Oncol; 2011 Jan; 12(1):8-9. PubMed ID: 21050812
    [No Abstract]   [Full Text] [Related]  

  • 5. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W
    Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of locally advanced pancreatic cancer with FOLFIRINOX].
    Strobel O; Büchler MW
    Chirurg; 2016 Aug; 87(8):699. PubMed ID: 27418266
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Okusaka T; Ikeda M; Fukutomi A; Ioka T; Furuse J; Ohkawa S; Isayama H; Boku N
    Cancer Sci; 2015 Aug; 106(8):1101-2. PubMed ID: 26268894
    [No Abstract]   [Full Text] [Related]  

  • 8. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma.
    Hashimoto M; Hikichi T; Suzuki T; Tai M; Ichii O; Matsuhashi N; Kita E; Takahashi S; Okubo Y; Hakozaki H; Ejiri Y; Ohira H
    Clin J Gastroenterol; 2017 Dec; 10(6):564-569. PubMed ID: 29052123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
    Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
    Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
    Zhu J; Strosberg JR; Dropkin E; Strickler JH
    J Gastrointest Cancer; 2015 Jun; 46(2):166-9. PubMed ID: 25662891
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of post-operative recurrence of pancreatic cancer in the residual pancreas treated by resection of the residual pancreas following radiological complete response achieved with second-line FOLFIRINOX].
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Mori R; Matsuyama R; Taniguchi K; Tanaka K; Akiyama H; Endo I; Ichikawa Y
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):901-4. PubMed ID: 25131881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
    Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
    Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
    Sasaki T; Isayama H; Aoki T; Tanaka M; Hamada T; Nakai Y; Sakamoto Y; Hasegawa K; Morikawa T; Fukayama M; Kokudo N; Koike K
    Pancreas; 2014 Aug; 43(6):972-4. PubMed ID: 25010709
    [No Abstract]   [Full Text] [Related]  

  • 16. [Second-line chemotherapy for advanced pancreatic cancer].
    Sato A; Saito K; Takahata T
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):403-7. PubMed ID: 25963687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
    Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
    Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 19. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.